Unknown

Dataset Information

0

Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.


ABSTRACT:

Background

Adoptive cell therapy has achieved great success in treating hematological malignancies. However, the production of chimeric antigen receptor T (CAR-T) cell therapy still faces various difficulties. Natural killer (NK)-92 is a continuously expandable cell line and provides a promising alternative for patient's own immune cells.

Methods

We established CAR-NK cells by co-expressing natural killer group 2 member D (NKG2D) and IL-21, and evaluated the efficacy of NKG2D-IL-21 CAR-NK cells in treating lung cancer in vitro and in vivo.

Results

Our data suggested that the expression of IL-21 effectively increased the cytotoxicity of NKG2D CAR-NK cells against lung cancer cells in a dose-dependent manner and suppressed tumor growth in vitro and in vivo. In addition, the proliferation of NKG2D-IL-21 CAR-NK cells were enhanced while the apoptosis and exhaustion of these cells were suppressed. Mechanistically, IL-21-mediated NKG2D CAR-NK cells function by activating AKT signaling pathway.

Conclusion

Our findings provide a novel option for treating lung cancer using NKG2D-IL-21 CAR-NK cell therapy.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC10807083 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer.

Zhang Yan Y   Zhang Cong C   He Minghong M   Xing Weipeng W   Hou Rui R   Zhang Haijin H  

BMC cancer 20240123 1


<h4>Background</h4>Adoptive cell therapy has achieved great success in treating hematological malignancies. However, the production of chimeric antigen receptor T (CAR-T) cell therapy still faces various difficulties. Natural killer (NK)-92 is a continuously expandable cell line and provides a promising alternative for patient's own immune cells.<h4>Methods</h4>We established CAR-NK cells by co-expressing natural killer group 2 member D (NKG2D) and IL-21, and evaluated the efficacy of NKG2D-IL-2  ...[more]

Similar Datasets

| S-EPMC7409228 | biostudies-literature
| S-EPMC9546681 | biostudies-literature
| S-EPMC11783442 | biostudies-literature
| S-EPMC8609108 | biostudies-literature
| 2402632 | ecrin-mdr-crc
| S-EPMC8969382 | biostudies-literature
| S-EPMC10187144 | biostudies-literature
| S-EPMC2782462 | biostudies-literature
| S-EPMC6538869 | biostudies-literature
| S-EPMC11604404 | biostudies-literature